Marksans Pharma Subsidiary Gains UK MHRA Approval for Cetirizine
Filing Summary
Marksans Pharma Ltd announced that its UK-based wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution. This authorization allows Relonchem to market the product in the UK. Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations globally, with facilities approved by major regulatory agencies.
Marksans Pharma Ltd announced that its wholly owned subsidiary, Relonchem Limited, based in the UK, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product, Cetirizine Dihydrochloride 1 mg/ml Oral Solution. This authorization permits the marketing of the product in the UK.
The announcement was made on November 20, 2025. The authorization is specific to the oral solution form of Cetirizine Dihydrochloride at a concentration of 1 mg/ml. The product is intended for use in the UK market following this regulatory approval.
Marksans Pharma Ltd is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company operates manufacturing facilities in India, the USA, and the UK, which are approved by several leading regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma’s product portfolio includes major therapeutic segments such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, anti-allergies, upper respiratory, oncology, and antibiotics. The company markets these products globally.